Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
8.88
+0.16 (1.83%)
Nov 5, 2024, 11:19 AM EST - Market open
Arcutis Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Operating Revenue | 74.06 | 29.19 | 3.69 | - | - | - | Upgrade
|
| Other Revenue | 58 | 30.42 | - | - | - | - | Upgrade
|
| Revenue | 132.06 | 59.61 | 3.69 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 1032.90% | 1517.09% | - | - | - | - | Upgrade
|
| Cost of Revenue | 10.15 | 4.99 | 0.75 | - | - | - | Upgrade
|
| Gross Profit | 121.91 | 54.62 | 2.93 | - | - | - | Upgrade
|
| Selling, General & Admin | 209.24 | 185.15 | 122.12 | 60.97 | 21.34 | 6.61 | Upgrade
|
| Research & Development | 92.45 | 110.58 | 182.44 | 145.56 | 115.31 | 36.52 | Upgrade
|
| Operating Expenses | 301.69 | 295.72 | 304.56 | 206.53 | 136.65 | 43.13 | Upgrade
|
| Operating Income | -179.77 | -241.1 | -301.63 | -206.53 | -136.65 | -43.13 | Upgrade
|
| Interest Expense | -30.29 | -29.71 | -15.65 | - | - | - | Upgrade
|
| Interest & Investment Income | 14.73 | 11.79 | 5.82 | 0.17 | 0.97 | 1.14 | Upgrade
|
| Pretax Income | -195.33 | -259.03 | -311.46 | -206.36 | -135.68 | -42 | Upgrade
|
| Income Tax Expense | 3.44 | 3.11 | - | - | - | - | Upgrade
|
| Net Income | -198.76 | -262.14 | -311.46 | -206.36 | -135.68 | -42 | Upgrade
|
| Net Income to Common | -198.76 | -262.14 | -311.46 | -206.36 | -135.68 | -42 | Upgrade
|
| Shares Outstanding (Basic) | 97 | 69 | 55 | 49 | 36 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 97 | 69 | 55 | 49 | 36 | 2 | Upgrade
|
| Shares Change (YoY) | 61.61% | 25.94% | 11.39% | 38.51% | 1835.11% | 48.68% | Upgrade
|
| EPS (Basic) | -2.04 | -3.78 | -5.66 | -4.18 | -3.80 | -22.78 | Upgrade
|
| EPS (Diluted) | -2.04 | -3.78 | -5.66 | -4.18 | -3.80 | -22.78 | Upgrade
|
| Free Cash Flow | -177.02 | -247.49 | -258.05 | -175.62 | -113.35 | -43.13 | Upgrade
|
| Free Cash Flow Per Share | -1.82 | -3.57 | -4.69 | -3.55 | -3.18 | -23.40 | Upgrade
|
| Gross Margin | 92.32% | 91.63% | 79.54% | - | - | - | Upgrade
|
| Operating Margin | -136.13% | -404.49% | -8183.04% | - | - | - | Upgrade
|
| Profit Margin | -150.51% | -439.79% | -8449.76% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -134.04% | -415.20% | -7000.76% | - | - | - | Upgrade
|
| EBITDA | -178.29 | -239.58 | -300.69 | -206.08 | -136.52 | -43.06 | Upgrade
|
| D&A For EBITDA | 1.48 | 1.52 | 0.93 | 0.45 | 0.12 | 0.07 | Upgrade
|
| EBIT | -179.77 | -241.1 | -301.63 | -206.53 | -136.65 | -43.13 | Upgrade
|
| Revenue as Reported | 132.06 | 59.61 | 3.69 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.